Quanterix Q2 revenue up 12% YoY, net income down 56% YoY.

• Quanterix reports Q2 2025 financial results • Biomarker detection company acquires Akoya Biosciences • Combined business has high-margin, high-throughput opportunity • Consumables revenue at $100mln on a pro forma basis • Academic market challenges impact growth • Accelerator business sees net increase in new customers • Project sizes reduced due to co-payments • Masoud Toloue, CEO, expects profitable growth in expanded market • Company demonstrates resilience despite US academic market challenges

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in ultra-sensitive biomarker detection, has reported its second quarter 2025 financial results. The company announced that it will host a conference call on August 7, 2025, at 4:30 p.m. E.T., to discuss these results [1].

Key Highlights:

- Revenue: Quanterix reported revenue of $24.5 million for the second quarter, a decrease of 29% compared to $34.4 million in the prior year. The company expects 2025 revenues to range between $130 million and $135 million, including approximately two quarters of performance from Akoya Biosciences [2].
- Gross Margin: The company's GAAP gross margin was 46.2%, compared to 64.7% in the prior year. The adjusted gross margin (non-GAAP) was 41.8%, down from 58.6% in the prior year [2].
- Net Loss: Quanterix reported a net loss of $30.0 million for the second quarter, compared to a net loss of $7.4 million in the prior year [2].
- Cash Position: The company ended the second quarter with $263.8 million in cash, cash equivalents, marketable securities, and restricted cash, representing a use of cash of approximately $5.7 million [2].
- Acquisition of Akoya Biosciences: In early July 2025, Quanterix completed the acquisition of Akoya Biosciences, adding multiplexed tissue imaging with single-cell resolution to its portfolio. This acquisition has positioned the company to offer a uniquely integrated platform that connects biology across blood and tissue, advancing precision medicine from discovery to diagnostics [2].

Operational and Business Highlights:

- Consumables Revenue: The combined business has generated approximately $100 million in consumables revenue on a pro forma basis [2].
- Academic Market Challenges: Despite near-term challenges in the US academic market, Quanterix has demonstrated resilience. The Accelerator business reported a net increase in new customers, despite smaller project sizes due to constrained biopharma budgets [2].
- Alzheimer’s Diagnostics: Revenues from Alzheimer’s Diagnostics more than tripled year-over-year [2].
- Regulatory Approvals: Quanterix’s UltraDx Plasma pTau-217 Assay Kit has successfully obtained medical device registration approval from the National Medical Product Agency (i.e., China’s FDA) [2].

Outlook:

Masoud Toloue, CEO of Quanterix, stated, "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market. We remain focused on maximizing the significant potential of the Akoya combination and achieving cash flow breakeven in 2026, even if end market conditions remain difficult" [2].

References:

[1] https://www.biospace.com/press-releases/quanterix-to-report-second-quarter-2025-financial-results-on-august-7-2025
[2] https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-second-quarter-2025